Use of Oral Contraceptives for Management of Acne Vulgaris

Practical Considerations in Real World Practice

      Keywords

      To read this article in full you will need to make a payment
      Purchase one-time access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.
      Subscribe to Dermatologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Arowojolu A.O.
        • Gallo M.F.
        • Lopez L.M.
        • et al.
        Combined oral contraceptive pills for treatment of acne.
        Cochrane Database Syst Rev. 2012; (CD004425)
        • Sitruk-Ware R.
        Pharmacology of different progestogens: the special case of drospirenone.
        Climacteric. 2005; 8: 4-12
        • Davtyan C.
        Four generations of progestins in oral contraceptives.
        Proceedings of UCLA Healthcare. 2012; 16: 1-3
        • Koulianos G.T.
        Treatment of acne with oral contraceptives: criteria for pill selection.
        Cutis. 2000; 66: 281-286
        • Rabe T.
        • Kowland A.
        • Ortmann J.
        • et al.
        Inhibition of skin 5 alpha reductase by oral contraceptive progestins in vitro.
        Gynecol Endocrinol. 2000; 14: 223-230
        • Palli M.B.
        • Reyes-Habito C.M.
        • Lima X.T.
        • et al.
        A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
        J Drugs Dermatol. 2013; 12: 633-637
        • Burkman R.
        • Schlesselman J.J.
        • Zieman M.
        Safety concerns and health benefits associated with oral contraception.
        Am J Obstet Gynecol. 2004; 190: S5-S22
      1. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development.
        N Engl J Med. 1987; 316: 650-655
        • Maguire K.
        • Westhoff C.
        The state of hormonal contraception today: established and emerging noncontraceptive health benefits.
        Am J Obstet Gynecol. 2011; 205: S4-S8
        • Weiss N.S.
        • Sayvetz T.A.
        Incidence of endometrial cancer in relation to the use of oral contraceptives.
        N Engl J Med. 1980; 302: 551-554
        • Lopez L.M.
        • Kaptein A.A.
        • Helmerhorst F.M.
        Oral contraceptives containing drospirenone for premenstrual syndrome.
        Cochrane Database Syst Rev. 2012; (CD006586)
        • deBastos M.
        • Stegeman B.H.
        • Rosendaal F.R.
        • et al.
        Combined oral contraceptives: venous thrombosis.
        Cochrane Database Syst Rev. 2014; (CD010813)
        • Raymond E.G.
        • Burke A.E.
        • Espey E.
        Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective.
        Obstet Gynecol. 2012; 119: 1039-1044
        • Jick S.S.
        • Hernandez R.K.
        Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: a case-control study using United States claims data.
        BMJ. 2011; 342: d2151
      2. FDA Office of Surveillance and Epidemiology. Combined hormonal contraceptives and the risk of cardiovascular disease endpoints. 2011. Available at: http://www.fda.gov/downloads/Drugs/Drug. Accessed March 01, 2015.

        • Committee on Gynecologic Practice
        ACOG Committee Opinion No. 540. Risk of venous thromboembolism among users of drospirenone-containing oral contraceptive pills.
        Obstet Gynecol. 2012; 120: 1239-1242
        • WHO
        Cardiovascular disease and steroid hormone contraception: report of a WHO Scientific Group.
        WHO Scientific Group on Cardiovascular Disease and Steroid Hormone Contraception, Geneva (Switzerland)1998 (WHO Technical Report No. 877)
        • Collaborative Group on Hormonal Factors in Breast Cancer
        Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies.
        Lancet. 1996; 347: 1713-1727
        • Gierisch J.M.
        • Coeytaux R.R.
        • Peragallo Urrutia R.
        • et al.
        Oral contraceptive use and trisk of breast, cervical, colorectal, and endometrial cancers: a systematic review.
        Cancer Epidemiol Biomarkers Prev. 2013; 22: 1931-1943
        • Appleby P.
        • Beral V.
        • et al.
        • International Collaboration of Epidemiological Studies of Cervical Cancer
        Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.
        Lancet. 2007; 370: 1609-1621
        • Agostino H.
        • DiMeglio G.
        Low-dose oral contraceptives in adolescents: how low can you go?.
        J Pediatr Adolesc Gynecol. 2010; 23: 195-201
        • Frangos J.E.
        • Alavian C.N.
        • Kimball A.B.
        Acne and oral contraceptives: update on women’s health screening guidelines.
        J Am Acad Dermatol. 2008; 58: 781-786
        • Somani N.
        • Harrison S.
        • Bergfeld W.
        The clinical evaluation of hirsutism.
        Dermatol Ther. 2008; 21: 376-391
        • Harper J.C.
        Evaluating hyperandrogenism: a challenge in acne management.
        J Drugs Dermatol. 2008; 7: 527-530
        • Buzney E.
        • Sheu J.
        • Buzney C.
        • et al.
        Polycystic ovary syndrome: a review for dermatologists Part II Treatment.
        J Am Acad Dermatol. 2014; 71: 859.e1-859.e15
        • Stewart F.H.
        • Harper C.C.
        • Ellertson C.E.
        • et al.
        Clinical breast and pelvic examination requirements for hormonal contraception.
        JAMA. 2001; 285: 2232-2239
        • Koltun W.
        • Maloney J.M.
        • Marr J.
        • et al.
        Treatment of moderate acne vulgaris unsing a combined oral contraceptive containing ethinylestradiol 20μg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis.
        Eur J Obstet Gynecol Reprod Biol. 2011; 155: 171-175
        • Maloney J.M.
        • Dietze P.
        • Watson D.
        • et al.
        A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20μg ethinyl estradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment.
        J Drugs Dermatol. 2009; 8: 837-844
        • Lucky A.W.
        • Koltun W.
        • Thiboutot D.
        • et al.
        A combined oral contraceptive containing 3mg drospirenone/20μg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
        Cutis. 2008; 82: 143-150
        • vanVloten W.A.
        • vanHaselen C.W.
        • van Zuuren E.J.
        • et al.
        The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
        Cutis. 2002; 69: 2-15
        • London B.M.
        • Lookingbill D.P.
        Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives.
        Arch Dermatol. 1994; 130: 392-393
        • Weisberg E.
        Interactions between oral contraceptives and antifungals/antibacterials; is contraceptive failure the result?.
        Clin Pharmacokinet. 1999; 36: 309-313
        • Brahmi D.
        • Curtis K.M.
        When can a woman start combination hormonal contraceptives (CHCs)?: a systematic review.
        Contraception. 2013; 87: 524-538
        • Tyler K.H.
        • Zirwas M.J.
        Contraception and the dermatologist.
        J Am Acad Dermatol. 2013; 68: 1022-1029
        • Gallo M.F.
        • Lopez L.M.
        • Grimes D.A.
        • et al.
        Combination contraceptives: effects on weight.
        Cochrane Database Syst Rev. 2008; (CD003987)